Warren Buffett's Successor Greg Abel Dumped 16 Stocks in Q1: Here Are the 2 Biggest Surprises

Berkshire Hathaway exited 16 positions in Q1 2026, including notable full sales of Amazon, UnitedHealth, Mastercard, Visa, Aon, and several Liberty-related holdings. The article frames Amazon and UnitedHealth as surprising exits but argues both remain attractive long-term opportunities, citing Amazon's AI and cloud growth potential and UnitedHealth's recovery from elevated medical costs. Overall the piece is commentary on portfolio reshuffling rather than a material company-specific catalyst.

Analysis

The biggest market signal here is not the sales themselves, but what they imply about process drift inside Berkshire: a cleaner, more rules-based portfolio purge tends to create forced supply in names that were never large enough to matter to Berkshire, but can still pressure sentiment in the near term. That matters most for higher-quality compounders like AMZN and UNH, where retail investors often over-interpret Berkshire action as a valuation signal rather than a portfolio-management event. In practice, these exits may create a 1-3 week dislocation as quant, event-driven, and headline-following flows lean the wrong way, but they do not change the fundamental earnings path.

AMZN is the more asymmetric beneficiary from a contrarian standpoint. The market still underappreciates how AI capex is monetized through cloud consumption, logistics automation, and ad targeting rather than just model providers; if AWS re-accelerates even modestly, the stock can rerate quickly because the market is already paying for a durability discount. UNH is a different setup: it is a mean-reversion trade on utilization normalization and rate adequacy, and the key second-order effect is that stabilization in Medicare Advantage could improve sentiment across managed care peers via multiple expansion, not just EPS recovery.

The main risk is that investors confuse a portfolio-cleanup event with a fundamental downgrade. For AMZN, the failure mode is any sign that cloud share gains are slowing while AI capex stays elevated, which would turn margin expansion into a longer-duration story and cap near-term upside. For UNH, the tail risk is that medical cost pressure proves structural rather than temporary; if loss ratios do not normalize over the next two quarters, the ‘cheap because it’s broken’ thesis becomes a value trap. The shortest-horizon trade is sentiment rebound over days to weeks; the base case for both is a 6-12 month recovery/reacceleration path.

Key Decisions for Investors

• Buy AMZN on headline-driven weakness over the next 1-2 weeks; target a 10-15% rebound if AWS/AI demand commentary remains constructive, with downside limited by diversified earnings streams.
• Add to UNH on any post-sale dip; use a 3-6 month horizon for mean reversion, with upside from medical cost normalization and multiple expansion if loss-ratio trends stabilize.
• Pair trade: long AMZN / short AON for 3-6 months. The long leg has secular AI and cloud reacceleration optionality; the short leg faces slower growth and less operating leverage, making this a cleaner growth-vs-stagnation expression.
• For more tactical accounts, sell cash-secured puts on AMZN 5-10% below spot into post-news volatility; thesis is to get paid while waiting for sentiment to reset.
• Avoid chasing the sold financials and consumer names immediately after the announcement; the likely setup is a short-lived supply overhang rather than a durable deterioration, so wait for either stabilization or lower entry levels.